Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement